Branded generic medicines marketed to Indian doctors through field forces and sold through chemists - the core of the Indian pharmaceutical market (IPM).
Sun Pharmaceutical IndustriesOperator · HighListed
Mankind PharmaOperator · HighListed
Torrent PharmaceuticalsOperator · HighListed
Alkem LaboratoriesOperator · HighListed
Abbott IndiaOperator · HighListed
Eris LifesciencesOperator · HighListed
CiplaOperator · MediumListed
Zydus LifesciencesOperator · MediumListed
Ipca LaboratoriesOperator · MediumListed
Ajanta PharmaOperator · MediumListed
Intas PharmaceuticalsOperator · HighUnlisted
Mankind Pharma (MANKIND)
India-focused branded generics leader - No. 1 by prescription volume, strong in tier-2/3 towns, plus OTC brands and (since 2024) Bharat Serums & Vaccines
Price
₹2,493
snapshot 30 Oct 2026
Strengths
Almost all revenue is domestic, so no US price-erosion or tariff exposure
Deep rural/semi-urban distribution and top-10 brands (Manforce, Prega News, Moxikind) built at low marketing cost
Bharat Serums & Vaccines acquisition adds women's health, critical care and biologics capability
Risks
Bharat Serums deal (~₹13,600 Cr EV) was debt-funded - FY26 profit slipped on interest and amortisation despite 17% revenue growth
Acute and mass-market mix is more exposed to NLEM price caps and trade-generic competition
Integration execution on a large acquisition is new for the company
Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Turns molecules into brands: companies in-license or make formulations, build them into doctor-recognised brands through large medical-representative (MR) field forces, and sell through ~65,000 stockists to India's chemists. In India almost every off-patent medicine is a 'branded generic', so brand and prescriber loyalty, not patents, decide market share.
Why it matters
This is the steadiest and highest-return profit pool in Indian pharma: no US-style price erosion, high gross margins (60-80%), modest capex and cash-rich balance sheets. It is also where the sector's best compounders (Sun's India business, Torrent, Abbott India, Mankind) live, and why consolidation deals in this layer command 30x+ EBITDA.
Where the value pool sits
Pharmarack puts the IPM at ~₹2.4L Cr for calendar 2025 (+8.1%), with August 2026 value growth of 10.7%. Growth is mostly price and new launches (annual WPI-linked hikes on NLEM drugs, freer pricing on non-scheduled brands); volume growth is near zero. Chronic therapies (cardiac, anti-diabetic, CNS, GI) grow faster and are stickier than acute ones (anti-infectives, respiratory), so chronic-heavy portfolios earn premium valuations.
Key drivers
Chronic disease burden (diabetes, hypertension, obesity) and rising insurance coverage
Patent expiries in India (sitagliptin 2022, empagliflozin 2025, semaglutide Mar 2026) creating large new branded-generic markets
Brand acquisitions from MNCs and smaller peers (Torrent-JB, Mankind-Bharat Serums, Eris-Biocon brands)
Annual WPI-linked price increases on scheduled drugs plus up to 10% a year on non-scheduled brands
Potential bottlenecks
Price control: ~15-18% of the market sits under NLEM/DPCO ceiling prices, and NPPA can cap trade margins or add drugs to the list
Field-force productivity - MR costs rise every year and incremental reps add less
Trade-generic and Jan Aushadhi channels pressure prices in commoditised molecules
Revised Schedule M (WHO-GMP aligned) raises compliance cost for smaller makers
Investor metrics to watch
IPM share and rank (Pharmarack / IQVIA)
Domestic growth vs IPM growth, split into price / volume / new launches